Product NDC: | 10019-957 |
Proprietary Name: | Cyclophosphamide |
Non Proprietary Name: | cyclophosphamide |
Active Ingredient(s): | 2 g/100mL & nbsp; cyclophosphamide |
Administration Route(s): | INTRAVENOUS; ORAL |
Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 10019-957 |
Labeler Name: | Baxter Healthcare Corporation |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA040745 |
Marketing Category: | ANDA |
Start Marketing Date: | 20080521 |
Package NDC: | 10019-957-01 |
Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-957-01) > 100 mL in 1 VIAL, SINGLE-DOSE (10019-957-11) |
NDC Code | 10019-957-01 |
Proprietary Name | Cyclophosphamide |
Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-957-01) > 100 mL in 1 VIAL, SINGLE-DOSE (10019-957-11) |
Product NDC | 10019-957 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | cyclophosphamide |
Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
Route Name | INTRAVENOUS; ORAL |
Start Marketing Date | 20080521 |
Marketing Category Name | ANDA |
Labeler Name | Baxter Healthcare Corporation |
Substance Name | CYCLOPHOSPHAMIDE |
Strength Number | 2 |
Strength Unit | g/100mL |
Pharmaceutical Classes | Alkylating Activity [MoA],Alkylating Drug [EPC] |